Abbott Laboratories

• Market Cap of USD 223 billion (50th largest globally), one of the larger medical devices company.
• Revenue of ~USD 42 billion (2024) - ,mainly diagnostic, nutritional and medical devices. Some pharma too.
• Although revenue declined from Covid times, the other streams have gone up. (Rapid Diagnostics declined)
• A broad base of revenue categories and countries
• Established Pharma Products in emerging markets, none in US USD 5 billion 
• Nutritional Products USD 8.4 billion (Adult and Pediatric)
• Diagnostic Products USD 9.341 billion
• Products sold by the Diagnostics segment include various types of diagnostic tests to detect COVID-19. Abbott’s COVID-19 testing-related sales totaled approximately $747 million in 2024, $1.6 billion in 2023 and $8.4 billion in 2022.
• Medical Devices 18.98 billion
• Diabetes care is largest category
• Abbott Lab is a leading player in this segment,
• Diabetes Care is a USD 65 billion
• Abbott’s products are generally sold directly to retailers, wholesalers, distributors, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
• 114000 employees
• At its height, covid testing market was $46 billion. Now less.
• Roche, Abbott, Hologic, Becton Dickinson and co, DiaSorin, and bioMerieux dominate the COVID-19 test market, covering more than 50% by value.
• The global covid-19 diagnostics market size was estimated at USD 33.03 billion in 2023 and is projected to reach USD 6.25 billion by 2030, declining at a CAGR of -21.2% from 2024 to 2030.